



an Open Access Journal by MDPI

## 10th Anniversary of Biomedicines—Pathogenesis and Innovative Therapies in Ovarian Cancer

Guest Editors:

**Dr. Francesca Magherini**

Department of Experimental and Clinical Biomedical Sciences “Mario Serio”, Università degli Studi di Firenze, Florence, Italy

**Dr. Tania Gamberi**

Department of Clinical and Preclinical Biomedical Sciences, University of Florence, Florence, Italy

Deadline for manuscript submissions:

**closed (30 April 2023)**

### Message from the Guest Editors

Ovarian Cancer is the most lethal gynecological disease and is characterized by heterogeneity, a high risk of relapse and the development of chemoresistance; Genetic and epigenetic factors and microenvironment characteristics influence the progression of the disease and its response to therapy. The cornerstone of treatment has been maximal-effort surgical cytoreduction combined with cytotoxic chemotherapy, mainly represented by combinations of carboplatin and paclitaxel, both in adjuvant and metastatic settings. An estimated 80–85% of patients with OC who achieve full remission following first-line platinum-based therapy will develop disease recurrence, and the median survival for these patients ranges from 12 months to 24 months. Except for bevacizumab and poly ADP-ribose polymerase inhibitors, there are few other options for women with platinum-resistant OC. It is, therefore, particularly important to deepen the pathobiology of the tumor itself, and further understand how it is influenced by the microenvironment and by the genetic heterogeneity present not only in cancer from different patients, but also within a single cancer.



[mdpi.com/si/1111042](https://mdpi.com/si/1111042)

# Special Issue



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPlus / SciFinder*, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](https://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
X@Biomed\_MDPI